GMAB
Genmab AS
35.60$
+0.6%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.6% | 27.5% | 18.0% | 67.2% | 33.5% | 24.7% | 63.6% | 26.5% | 27.0% | 44.8% | 36.1% | 31.9% | |
| 1.5% | 2.8% | 2.3% | 2.9% | 2.9% | 2.6% | 2.6% | 2.9% | 2.5% | 1.8% | 1.9% | 1.9% | |
| 3.3% | 3.2% | 2.9% | 3.2% | 3.0% | 2.7% | 2.0% | 3.7% | 3.0% | 3.6% | 3.3% | 3.4% | |
| – | 0.0% | -2.3% | 8.4% | 2.9% | 3.9% | 4.2% | -3.7% | -0.5% | – | – | – | |
| 4.8% | -23.5% | -43.8% | 11.4% | -21.0% | -22.7% | 3.0% | -9.1% | -13.3% | 8.3% | -7.4% | 6.0% | |
| 8.9% | 11.9% | 1.8% | 3.7% | 15.8% | 2.1% | 3.0% | 3.0% | 2.2% | 2.3% | 0.9% | 1.0% | |
| -118.8% | -42.4% | -55.9% | -28.2% | -58.8% | -37.0% | -23.3% | -11.4% | -19.0% | -7.8% | -46.0% | -151.7% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 1.1% | 1.6% | 1.9% | – | – | – | |
| – | 56.8% | -6.5% | 0.0% | -4.8% | -0.2% | -0.2% | -5.3% | -6.3% | -3.4% | -18.5% | -11.6% | |
| – | 0.0% | 0.0% | -1.3% | -1.0% | -0.6% | -0.4% | -0.7% | -0.5% | -0.1% | 0.0% | -0.3% | |
| 121.8% | 56.8% | 5.0% | 9.1% | -2.3% | 68.2% | 0.7% | -5.0% | -5.4% | -3.7% | -18.2% | 128.7% | |
| 22.5% | 45.4% | -31.2% | 44.0% | -26.9% | 56.3% | 36.7% | 20.2% | 6.5% | 30.2% | -23.3% | 9.3% | |
| 6.7% | 15.5% | 16.2% | 63.4% | 17.8% | 22.6% | 60.6% | 23.5% | 24.8% | 42.5% | 35.2% | 30.9% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.